VR을 이용한 ADHD 진단을 위한 디지털 치료제

  • 손하민 ((주)히포티앤씨, 성균관대학교) ;
  • 이준희 ((주)히포티앤씨, 성균관대학교) ;
  • 최정훈 ((주)히포티앤씨, 성균관대학교) ;
  • 정태명 ((주)히포티앤씨, 성균관대학교)
  • Published : 2022.01.30

Abstract

해마다 정신 질환의 발병률은 높아지지만, 이를 위한 진단과 치료의 한계는 현재까지도 해결되지 않고 있다. 디지털 치료제(DTx)는 이러한 한계를 극복할 수 있는 새로운 해결법으로 화두되고 있다. 본 연구는 객관적인 ADHD 진단을 위한 Hippo T&C의 디지털 치료 솔루션인 AttnKare-D를 제안한다. AttnKare-D는 정신 질환의 진단 및 통계 편람(DSM-5)에 따라 통제된 환경에서 데이터를 정량화함으로써 진단을 객관화한다. 또한, ADHD의 세부적 증상에 대한 상세한 보고서를 만듦으로써, 넓은 분류보다는 특정한 증상들에 집중하여 치료를 개인화한다. 적절한 샘플 사이즈에 낮은 오류율을 보이므로 임상 환경에서 AttnKare-D는 긍정적인 가능성을 보여준다.

Keywords

References

  1. National Institute of Mental Health (NIH), Mental Illness, https://www.nimh.nih.gov/health/statistics/mental-illness, 2019
  2. K., Manasi, and P. Kumar, "Impact of pandemic on mental health in lower-and middle-income countries (LMICs).", Global Mental Health 7, 2020
  3. Cho, Chul-Hyun, and Heon-Jeong Lee, "Could digital therapeutics be a game changer in psychiatry?.", Psychiatry investigation 16.2, (2019): 97. https://doi.org/10.30773/pi.2019.01.20
  4. Digital Therapeutics Alliance. https://dtxalliance.org/
  5. Sverdlov, Oleksandr, et al. "Digital therapeutics: an integral component of digital innovation in drug development." Clinical Pharmacology & Therapeutics 104.1 (2018): 72-80. https://doi.org/10.1002/cpt.1036
  6. Patel, Nisarg A., and Atul J. Butte. "Characteristics and challenges of the clinical pipeline of digital therapeutics.", NPJ digital medicine 3.1 (2020): 1-5. https://doi.org/10.1038/s41746-019-0211-0
  7. APA (2013), "Diagnostic and statistical manual of mental disorders, fifth edition, DSM-5", Arlington: American Psychiatric Association, APA
  8. Fulton F. Velez, et al. Real-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorder, Vol. 49 No. 5, pp. 341-347. https://doi.org/10.1080/21548331.2021.1956256
  9. Frances P. Thorndike, et al. Protocol for Digital Real-world Evidence trial for Adults with insomnia treated via Mobile (DREAM): an open-label trial of a prescription digital therapeutic for treating patients with chronic insomnia, Vol. 10 No. 7, pp. 569-581. https://doi.org/10.2217/cer-2021-0004
  10. NightWare. "NightWare Improves Sleep in Patients with Nightmare Disorder." NightWare, 1 July 2021, nightware.com.
  11. Garcia LM, Birckhead BJ, Krishnamurthy P, et al. An 8-Week Self-Administered At-Home Behavioral Skills-Based Virtual Reality Program for Chronic Low Back Pain: Double-Blind, Randomized, Placebo-Controlled Trial Conducted During COVID-19. J Med Internet Res. 2021;23(2):e26292. https://doi.org/10.2196/26292
  12. Cognoa, "Canvas Dx.", CanvasDx, canvasdx.com. Accessed 17 Jan. 2022.
  13. Boucher E, McNaughton E, Harake N, Stafford J, Parks A, The Impact of a Digital Intervention (Happify) on Loneliness During COVID-19: Qualitative Focus Group, JMIR Ment Health 2021;8(2):e26617 https://doi.org/10.2196/26617
  14. Scott H. Kollins, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial, Vol. 2 No. 4, pp. 168-178
  15. Son, H.M., et al. A novel approach to diagnose ADHD using virtual reality. International Journal of Web Information Systems, Vol. 17 No. 5, pp. 516-536. https://doi.org/10.1108/IJWIS-03-2021-0021
  16. Rosvold, H.E., et al. (1956), "A continuous performance test of brain damage", Journal of Consulting Psychology, Vol. 20 No. 5, pp. 343-350. https://doi.org/10.1037/h0043220
  17. Wechsler, David, and Habuku Kodama. Wechsler intelligence scale for children. New York: Psychological corporation, 1949.
  18. DuPaul, G., J, et al. (1998), ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation, New York, NY, The Guilford Press.